Biomarkers of HIV-1-associated neurocognitive disorders

Challenges of proteomic approaches

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

HIV-1 enters the brain shortly after infection, which may lead to neurological complications and in the most severe cases to encephalitis, dementia and death. The introduction of antiretroviral therapy reduced the incidence of the most severe conditions, nevertheless, approximately half of those infected with this virus will suffer to various degrees from HIV-1-associated neurocognitive disorders. Despite many years of research, there are no biomarkers that can objectively measure and, more importantly, predict the onset and the tempo of HIV-1-associated neurocognitive disorders. Here we review biomarker candidates of neurocognitive impairment due to HIV infection of the brain that have been proposed during the last two decades, and discuss perspectives and limitations of proteomic approaches in the search for new, more sensitive and specific biomarkers.

Original languageEnglish (US)
Pages (from-to)771-785
Number of pages15
JournalBiomarkers in Medicine
Volume3
Issue number6
DOIs
StatePublished - Dec 1 2009

Fingerprint

Biomarkers
Proteomics
HIV-1
Brain
Encephalitis
Viruses
HIV Infections
Dementia
Incidence
Infection
Research
Neurocognitive Disorders
Therapeutics

Keywords

  • AIDS
  • Biomarker
  • Cerebrospinal fluid
  • Cognitive impairment
  • Dementia
  • HAD
  • HAND
  • HIV
  • Plasma
  • Proteomics

ASJC Scopus subject areas

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Biomarkers of HIV-1-associated neurocognitive disorders : Challenges of proteomic approaches. / Ciborowski, Pawel S.

In: Biomarkers in Medicine, Vol. 3, No. 6, 01.12.2009, p. 771-785.

Research output: Contribution to journalReview article

@article{2e717d079eb042aa8695ca375378469f,
title = "Biomarkers of HIV-1-associated neurocognitive disorders: Challenges of proteomic approaches",
abstract = "HIV-1 enters the brain shortly after infection, which may lead to neurological complications and in the most severe cases to encephalitis, dementia and death. The introduction of antiretroviral therapy reduced the incidence of the most severe conditions, nevertheless, approximately half of those infected with this virus will suffer to various degrees from HIV-1-associated neurocognitive disorders. Despite many years of research, there are no biomarkers that can objectively measure and, more importantly, predict the onset and the tempo of HIV-1-associated neurocognitive disorders. Here we review biomarker candidates of neurocognitive impairment due to HIV infection of the brain that have been proposed during the last two decades, and discuss perspectives and limitations of proteomic approaches in the search for new, more sensitive and specific biomarkers.",
keywords = "AIDS, Biomarker, Cerebrospinal fluid, Cognitive impairment, Dementia, HAD, HAND, HIV, Plasma, Proteomics",
author = "Ciborowski, {Pawel S}",
year = "2009",
month = "12",
day = "1",
doi = "10.2217/bmm.09.63",
language = "English (US)",
volume = "3",
pages = "771--785",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Biomarkers of HIV-1-associated neurocognitive disorders

T2 - Challenges of proteomic approaches

AU - Ciborowski, Pawel S

PY - 2009/12/1

Y1 - 2009/12/1

N2 - HIV-1 enters the brain shortly after infection, which may lead to neurological complications and in the most severe cases to encephalitis, dementia and death. The introduction of antiretroviral therapy reduced the incidence of the most severe conditions, nevertheless, approximately half of those infected with this virus will suffer to various degrees from HIV-1-associated neurocognitive disorders. Despite many years of research, there are no biomarkers that can objectively measure and, more importantly, predict the onset and the tempo of HIV-1-associated neurocognitive disorders. Here we review biomarker candidates of neurocognitive impairment due to HIV infection of the brain that have been proposed during the last two decades, and discuss perspectives and limitations of proteomic approaches in the search for new, more sensitive and specific biomarkers.

AB - HIV-1 enters the brain shortly after infection, which may lead to neurological complications and in the most severe cases to encephalitis, dementia and death. The introduction of antiretroviral therapy reduced the incidence of the most severe conditions, nevertheless, approximately half of those infected with this virus will suffer to various degrees from HIV-1-associated neurocognitive disorders. Despite many years of research, there are no biomarkers that can objectively measure and, more importantly, predict the onset and the tempo of HIV-1-associated neurocognitive disorders. Here we review biomarker candidates of neurocognitive impairment due to HIV infection of the brain that have been proposed during the last two decades, and discuss perspectives and limitations of proteomic approaches in the search for new, more sensitive and specific biomarkers.

KW - AIDS

KW - Biomarker

KW - Cerebrospinal fluid

KW - Cognitive impairment

KW - Dementia

KW - HAD

KW - HAND

KW - HIV

KW - Plasma

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=75149148831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149148831&partnerID=8YFLogxK

U2 - 10.2217/bmm.09.63

DO - 10.2217/bmm.09.63

M3 - Review article

VL - 3

SP - 771

EP - 785

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 6

ER -